US FDA Lifts Clinical Hold On Gilead’s Lenacapavir HIV Treatment
Gilead Sciences, Inc. announced that, the Food and Drug Administration (FDA) of the United States has lifted the clinical hold, which was place on the Investigational New Drug (IND) Application of the company for the purpose of evaluating the injectable lenacapavir for the treatment of HIV and HIV pre-exposure prophylaxis (PrEP). As announced in the […]
Continue Reading